Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

2 x 2 Factorial randomized phase III study of intermittent oral capecitabine in combination with intravenous oxaliplatin (q3w) ("XELOX") with/without intravenous bevacizumab (q3w) versus bolus and continuous infusion fluorouracil/intravenous leucovorin with intravenous oxaliplatin (q2w) ("FOLFOX-4") with/without intravenous bevacizumab (q2w) as first-line treatment for patients with metastatic colorectal cancer.
capecitabine
NO16966
NCT00069095
metastatic colorectal cancer
Phase 3
 
January 2014

Powered by ideaPoint, Inc.